<![CDATA[Gabelli Healthcare & Wellness Trust]]>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED

MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number            811-22021                   

 

                             The Gabelli Healthcare & WellnessRx Trust                             

(Exact name of registrant as specified in charter)

One Corporate Center

                                 Rye, New York 10580-1422                                

(Address of principal executive offices) (Zip code)

Agnes Mullady

Gabelli Funds, LLC

One Corporate Center

                                 Rye, New York 10580-1422                                 

(Name and address of agent for service)

Registrant’s telephone number, including area code:  1-800-422-3554

Date of fiscal year end:  December 31

Date of reporting period:  March 31, 2014

Form N-Q is to be used by management investment companies, other than small business investment companies registered on Form N-5 (§§ 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than 60 days after the close of the first and third fiscal quarters, pursuant to rule 30b1-5 under the Investment Company Act of 1940 (17 CFR 270.30b1-5). The Commission may use the information provided on Form N-Q in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-Q, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-Q unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.


Item 1. Schedule of Investments.

The Schedule(s) of Investments is attached herewith.


The Gabelli Healthcare & WellnessRx Trust

First Quarter Report — March 31, 2014

Portfolio Management Team

 

LOGO

To Our Shareholders,

For the quarter ended March 31, 2014, the net asset value (“NAV”) total return of The Gabelli Healthcare & WellnessRx Trust (the “Fund”) was 3.1%, compared with a total return of 5.8% for the Standard & Poor’s (“S&P”) 500 Health Care Index. The total return for the Fund’s publicly traded shares was 0.8%. The Fund’s NAV per share was $11.56, while the price of the publicly traded shares closed at $10.34 on the New York Stock Exchange (“NYSE”). See below for additional performance information.

Enclosed is the schedule of investments as of March 31, 2014.

Comparative Results

 

Average Annual Returns through March 31, 2014 (a) (Unaudited)

     Quarter      1 Year     3 Year     5 Year     Since
Inception
(06/28/07)
 

Gabelli Healthcare & WellnessRx Trust

           

NAV Total Return (b)

     3.10%         23.70     21.10     22.83     11.34%    

Investment Total Return (c)

     0.76            17.50        20.15        25.07        9.03       

S&P 500 Health Care Index

     5.81            29.24        23.49        21.64        9.99       

S&P 500 Index

     1.81            21.86        14.66        21.16        5.59(d)   

S&P 500 Consumer Staples Index

     0.50            10.65        16.01        18.59        10.22       

50% S&P 500 Health Care Index and
50% S&P 500 Consumer Staples Index

     3.16            19.95        19.75        20.12        10.11       

 

  (a)

Returns represent past performance and do not guarantee future results. Investment returns and the principal value of an investment will fluctuate. When shares are sold, they may be worth more or less than their original cost. Current performance may be lower or higher than the performance data presented. Visit www.gabelli.com for performance information as of the most recent month end. Performance returns for periods of less than one year are not annualized. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The S&P 500 Health Care Index is an unmanaged indicator of health care equipment and services, pharmaceuticals, biotechnology, and life sciences stock performance. The S&P 500 Index is an unmanaged indicator of stock market performance. The S&P 500 Consumer Staples Index is an unmanaged indicator of food and staples retailing, food, beverage and tobacco, and household and personal products stock performance. Dividends are considered reinvested. You cannot invest directly in an index.

 

 

  (b)

Total returns and average annual returns reflect changes in the NAV per share, reinvestment of distributions at NAV on the ex-dividend date, and adjustments for rights offerings and are net of expenses. Since inception return is based on an initial NAV of $8.00.

 

 

  (c)

Total returns and average annual returns reflect changes in closing market values on the NYSE, reinvestment of distributions, and adjustments for rights offerings. Since inception return is based on an initial offering price of $8.00.

 

 

  (d)

From June 30, 2007, the date closest to the Fund’s inception for which data is available.

 

 


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments — March 31, 2014 (Unaudited)

 

 

 

Shares

         

Market

Value

 
  

COMMON STOCKS — 93.9%

  

  

Beverages — 7.9%

  

  25,000      

Campbell Soup Co.

   $ 1,122,000   
  30,000      

Danone SA

     2,121,454   
  45,000      

Dr Pepper Snapple Group Inc.

     2,450,700   
  26,000      

ITO EN Ltd.

     581,892   
  15,000      

Morinaga Milk Industry Co. Ltd.

     48,249   
  360,000      

Parmalat SpA

     1,240,883   
  35,000      

PepsiCo Inc.

     2,922,500   
  30,000      

Suntory Beverage & Food Ltd.

     1,033,280   
  60,000      

The Coca-Cola Co.

     2,319,600   
  60,000      

The WhiteWave Foods Co., Cl. A†

     1,712,400   
  424,000      

Vitasoy International Holdings Ltd.

     615,515   
     

 

 

 
        16,168,473   
     

 

 

 
  

Biotechnology — 3.1%

  

  20,000      

Amgen Inc.

     2,466,800   
  25,000      

Gilead Sciences Inc.†

     1,771,500   
  7,000      

Illumina Inc.†

     1,040,620   
  100,000      

Lexicon Pharmaceuticals Inc.†

     173,000   
  275,000      

NeoGenomics Inc.†

     954,250   
     

 

 

 
        6,406,170   
     

 

 

 
  

Computer Software and Services — 1.2%

  

  90,000      

Computer Task Group Inc.

     1,529,100   
  40,000      

MedAssets Inc.†

     988,400   
     

 

 

 
        2,517,500   
     

 

 

 
  

Consumer Services and Supplies — 2.4%

  

  108,000      

Hi-Tech Pharmacal Co. Inc.†

     4,679,640   
  15,000      

Weight Watchers International Inc.

     308,100   
     

 

 

 
        4,987,740   
     

 

 

 
  

Food — 21.4%

  

  84,000      

Boulder Brands Inc.†

     1,480,080   
  7,000      

Calavo Growers Inc.

     249,060   
  80,000      

ConAgra Foods Inc.

     2,482,400   
  8,000      

Dean Foods Co.

     123,680   
  67,500      

Flowers Foods Inc.

     1,447,875   
  60,000      

General Mills Inc.

     3,109,200   
  70,200      

Inventure Foods Inc.†

     981,396   
  38,000      

Kellogg Co.

     2,382,980   
  34,000      

Kerry Group plc, Cl. A

     2,583,713   
  150,000      

Kikkoman Corp.

     2,829,531   
  25,000      

Kraft Foods Group Inc.

     1,402,500   
  55,000      

Lifeway Foods Inc.

     808,500   
  10,000      

MEIJI Holdings Co. Ltd.

     630,722   
  80,000      

Mondelēz International Inc., Cl. A

     2,764,000   
  66,000      

Nestlé SA

     4,968,384   
  17,200      

Post Holdings Inc.†

     948,064   
  6,000      

Rock Field Co. Ltd.

     113,763   
  50,000      

Snyder’s-Lance Inc.

     1,409,500   
  15,700      

The Hain Celestial Group Inc.†

     1,436,079   
  90,000      

The Hillshire Brands Co.

     3,353,400   

Shares

         

Market

Value

 
  24,000      

The J.M. Smucker Co.

   $ 2,333,760   
  110,000      

Tingyi (Cayman Islands) Holding Corp.

     315,542   
  60,000      

Unilever plc, ADR

     2,566,800   
  63,000      

Yakult Honsha Co. Ltd.

     3,161,750   
     

 

 

 
        43,882,679   
     

 

 

 
  

Food and Staples Retailing — 8.3%

  

  20,000      

CST Brands Inc.

     624,800   
  77,000      

CVS Caremark Corp.

     5,764,220   
  25,000      

GNC Holdings Inc., Cl. A

     1,100,500   
  30,000      

Ingles Markets Inc., Cl. A

     714,600   
  1,000      

Nutraceutical International Corp.†

     25,990   
  7,000      

The Fresh Market Inc.†

     235,200   
  40,000      

The Kroger Co.

     1,746,000   
  30,000      

United Natural Foods Inc.†

     2,127,600   
  18,882      

Vitamin Shoppe, Inc.†

     897,273   
  10,000      

Walgreen Co.

     660,300   
  59,000      

Whole Foods Market Inc.

     2,991,890   
     

 

 

 
        16,888,373   
     

 

 

 
  

Health Care Equipment and Supplies — 14.4%

  

  15,000      

ARAMARK Holdings Corp.

     433,800   
  35,000      

Baxter International Inc.

     2,575,300   
  10,000      

Becton, Dickinson and Co.

     1,170,800   
  46,000      

Boston Scientific Corp.†

     621,920   
  28,000      

Covidien plc

     2,062,480   
  30,000      

Cutera Inc.†

     335,700   
  8,000      

Exactech Inc.†

     180,480   
  35,000      

Gerresheimer AG

     2,265,041   
  44,208      

Greatbatch Inc.†

     2,030,031   
  9,400      

Henry Schein Inc.†

     1,122,078   
  16,000      

Hospira Inc.†

     692,000   
  20,000      

ICU Medical Inc.†

     1,197,600   
  15,000      

Masimo Corp.†

     409,650   
  35,000      

Medtronic Inc.

     2,153,900   
  19,090      

Perrigo Co. plc

     2,952,459   
  50,000      

Sparton Corp.†

     1,464,000   
  35,000      

St. Jude Medical Inc.

     2,288,650   
  25,000      

Stryker Corp.

     2,036,750   
  25,000      

The Cooper Companies Inc.

     3,434,000   
     

 

 

 
        29,426,639   
     

 

 

 
  

Health Care Providers and Services — 15.2%

  

  279,924      

AdCare Health Systems Inc.†

     1,164,484   
  25,000      

Aetna Inc.

     1,874,250   
  80,000      

Alere Inc.†

     2,748,000   
  35,000      

AmerisourceBergen Corp.

     2,295,650   
  31,701      

Chemed Corp.

     2,835,655   
  25,000      

Cigna Corp.

     2,093,250   
  51,000      

DaVita HealthCare Partners Inc.†

     3,511,350   
  25,000      

Gentiva Health Services Inc.†

     228,000   
  55,000      

HCA Holdings Inc.†

     2,887,500   
  7,500      

Humana Inc.

     845,400   
 

 

See accompanying notes to schedule of investments.

 

2


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments (Continued) — March 31, 2014 (Unaudited)

 

 

 

Shares

         

Market

Value

 
  

COMMON STOCKS (Continued)

  

  

Health Care Providers and Services (Continued)

  

  1,500      

Laboratory Corp. of America Holdings†

   $ 147,315   
  17,500      

McKesson Corp.

     3,089,975   
  65,000      

Quality Systems Inc.

     1,097,200   
  45,000      

Rhoen Klinikum AG

     1,441,374   
  46,000      

Tenet Healthcare Corp.†

     1,969,260   
  36,000      

UnitedHealth Group Inc.

     2,951,640   
     

 

 

 
        31,180,303   
     

 

 

 
  

Hotels and Gaming — 0.2%

  

  7,921      

Ryman Hospitality Properties Inc.

     336,801   
     

 

 

 
  

Household and Personal Products — 3.7%

  

  18,000      

Avon Products Inc.

     263,520   
  20,000      

Church & Dwight Co. Inc.

     1,381,400   
  15,000      

Colgate-Palmolive Co.

     973,050   
  130,000      

Coty Inc., Cl. A

     1,947,400   
  20,000      

Sally Beauty Holdings Inc.†

     548,000   
  12,000      

The Estee Lauder Companies Inc., Cl. A

     802,560   
  20,000      

The Procter & Gamble Co.

     1,612,000   
     

 

 

 
        7,527,930   
     

 

 

 
  

Pharmaceuticals — 15.7%

  

  30,000      

Abbott Laboratories

     1,155,300   
  26,800      

Actavis plc†

     5,516,780   
  65,000      

Akorn Inc.†

     1,430,000   
  1,000      

Allergan Inc.

     124,100   
  350,000      

BioScrip Inc.†

     2,443,000   
  42,000      

Bristol-Myers Squibb Co.

     2,181,900   
  51,756      

Columbia Laboratories Inc.†

     373,678   
  68,000      

Express Scripts Holding Co.†

     5,106,120   
  42,000      

Johnson & Johnson

     4,125,660   
  3,842      

Liberator Medical Holdings Inc.

     15,099   
  30,000      

Medivation Inc.†

     1,931,100   
  50,000      

Merck & Co. Inc.

     2,838,500   
  45,000      

Mylan Inc.†

     2,197,350   
  72,000      

Pfizer Inc.

     2,312,640   
  12,000      

Roche Holding AG, ADR

     452,640   
  1,000      

Zoetis Inc.

     28,940   
     

 

 

 
        32,232,807   
     

 

 

 
  

Specialty Chemicals — 0.4%

  

  10,000      

FMC Corp.

     765,600   
     

 

 

 
  

TOTAL COMMON STOCKS

     192,321,015   
     

 

 

 

Shares

         

Market

Value

 
  

RIGHTS — 0.0%

  

  

Health Care — 0.0%

  

  40,000      

American Medical Alert Corp.†

   $ 400   
  20,000      

Cubist Pharmaceuticals Inc., CVR†

     13,000   
  130,000      

Trius Therapeutics, CVR†

     16,900   
     

 

 

 
  

TOTAL RIGHTS

     30,300   
     

 

 

 

Principal

Amount

             
  

U.S. GOVERNMENT OBLIGATIONS — 6.1%

  

$ 12,535,000      

U.S. Treasury Bills,
0.045% to 0.070%††,
05/22/14 to 08/21/14

     12,533,277   
     

 

 

 
  

TOTAL INVESTMENTS — 100.0%
(Cost $147,057,469)

   $ 204,884,592   
     

 

 

 
  

Aggregate tax cost

   $ 147,663,243   
     

 

 

 
  

Gross unrealized appreciation

   $ 59,080,164   
  

Gross unrealized depreciation

     (1,858,815
     

 

 

 
  

Net unrealized appreciation/depreciation

   $ 57,221,349   
     

 

 

 

 

Non-income producing security.

††

Represents annualized yield at date of purchase.

ADR

American Depositary Receipt

CVR

Contingent Value Right

 

Geographic Diversification

  

% of

Market

Value

   

Market

Value

 

North America

     83.1   $ 170,334,800   

Europe

     12.3        25,219,549   

Japan

     4.1        8,399,186   

Asia/Pacific

     0.5        931,057   
  

 

 

   

 

 

 

Total Investments

     100.0   $ 204,884,592   
  

 

 

   

 

 

 
 

See accompanying notes to schedule of investments.

 

3


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited)

 

 

 

The Fund’s schedule of investments is prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), which may require the use of management estimates and assumptions. Actual results could differ from those estimates. The following is a summary of significant accounting policies followed by the Fund in the preparation of its schedule of investments.

Security Valuation. Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market’s official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the “Board”) so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC (the “Adviser”).

Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market, but prior to the close of business on the day the securities are being valued. Debt instruments with remaining maturities of sixty days or less that are not credit impaired are valued at amortized cost, unless the Board determines such amount does not reflect the securities’ fair value, in which case these securities will be fair valued as determined by the Board. Debt instruments having a maturity greater than sixty days for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price. U.S. government obligations with maturities greater than sixty days are normally valued using a model that incorporates market observable data such as reported sales of similar securities, broker quotes, yields, bids, offers, and reference data. Certain securities are valued principally using dealer quotations. Futures contracts are valued at the closing settlement price of the exchange or board of trade on which the applicable contract is traded.

Securities and assets for which market quotations are not readily available are fair valued as determined by the Board. Fair valuation methodologies and procedures may include, but are not limited to: analysis and review of available financial and non-financial information about the company; comparisons with the valuation and changes in valuation of similar securities, including a comparison of foreign securities with the equivalent U.S. dollar value American Depositary Receipt securities at the close of the U.S. exchange; and evaluation of any other information that could be indicative of the value of the security.

The inputs and valuation techniques used to measure fair value of the Fund’s investments are summarized into three levels as described in the hierarchy below:

 

   

Level 1 — quoted prices in active markets for identical securities;

   

Level 2 — other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and

   

Level 3 — significant unobservable inputs (including the Board’s determinations as to the fair value of investments).

 

4


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited) (Continued)

 

 

 

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input both individually and in the aggregate that is significant to the fair value measurement. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of the Fund’s investments in securities by inputs used to value the Fund’s investments as of March 31, 2014 is as follows:

 

     Valuation Inputs         
     Level 1
Quoted Prices
     Level 2 Other Significant
Observable Inputs
     Level 3 Significant
Unobservable Inputs
     Total Market Value
at 3/31/14
 

INVESTMENTS IN SECURITIES:

           

ASSETS (Market Value):

           

Common Stocks(a)

     $192,321,015         —                 —                 $192,321,015   

Rights(a)

     13,000         —                 $17,300                 30,300   

U.S. Government Obligations

             $12,533,277                 —                 12,533,277   

TOTAL INVESTMENTS IN SECURITIES – ASSETS

     $192,334,015         $12,533,277                 $17,300                 $204,884,592   

 

(a)

Please refer to the Schedule of Investments for the industry classifications of these portfolio holdings.

The Fund did not have transfers among Level 1, Level 2, and Level 3 during the period ended March 31, 2014. The Fund’s policy is to recognize transfers among Levels as of the beginning of the reporting period.

Additional Information to Evaluate Qualitative Information.

General. The Fund uses recognized industry pricing services – approved by the Board and unaffiliated with the Adviser – to value most of its securities, and uses broker quotes provided by market makers of securities not valued by these and other recognized pricing sources. Several different pricing feeds are received to value domestic equity securities, international equity securities, preferred equity securities, and fixed income securities. The data within these feeds is ultimately sourced from major stock exchanges and trading systems where these securities trade. The prices supplied by external sources are checked by obtaining quotations or actual transaction prices from market participants. If a price obtained from the pricing source is deemed unreliable, prices will be sought from another pricing service or from a broker/dealer that trades that security or similar securities.

Fair Valuation. Fair valued securities may be common and preferred equities, warrants, options, rights, and fixed income obligations. Where appropriate, Level 3 securities are those for which market quotations are not available, such as securities not traded for several days, or for which current bids are not available, or which are restricted as to transfer. Among the factors to be considered to fair value a security are recent prices of comparable securities that are publicly traded, reliable prices of securities not publicly traded, the use of valuation models, current analyst reports, valuing the income or cash flow of the issuer, or cost if the preceding factors do not apply. A significant change in the unobservable inputs could result in a lower or higher value in Level 3 securities. The circumstances of Level 3 securities are frequently monitored to determine if fair valuation measures continue to apply.

The Adviser reports quarterly to the Board the results of the application of fair valuation policies and procedures. These include back testing the prices realized in subsequent trades of these fair valued securities to fair values previously recognized.

 

5


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited) (Continued)

 

 

 

Derivative Financial Instruments. The Fund may engage in various portfolio investment strategies by investing in a number of derivative financial instruments for the purposes of increasing the income of the Fund, hedging against changes in the value of its portfolio securities and in the value of securities it intends to purchase, or hedging against a specific transaction with respect to either the currency in which the transaction is denominated or another currency. Investing in certain derivative financial instruments, including participation in the options, futures, or swap markets, entails certain execution, liquidity, hedging, tax, and securities, interest, credit, or currency market risks. Losses may arise if the Adviser’s prediction of movements in the direction of the securities, foreign currency, and interest rate markets is inaccurate. Losses may also arise if the counterparty does not perform its duties under a contract, or that, in the event of default, the Fund may be delayed in or prevented from obtaining payments or other contractual remedies owed to it under derivative contracts. The creditworthiness of the counterparties is closely monitored in order to minimize these risks. Participation in derivative transactions involves investment risks, transaction costs, and potential losses to which the Fund would not be subject absent the use of these strategies. The consequences of these risks, transaction costs, and losses may have a negative impact on the Fund’s ability to pay distributions.

The Fund’s derivative contracts held at March 31, 2014, if any, are not accounted for as hedging instruments under GAAP and are disclosed in the Schedule of Investments together with the related counterparty.

Forward Foreign Exchange Contracts. The Fund may engage in forward foreign exchange contracts for the purpose of hedging a specific transaction with respect to either the currency in which the transaction is denominated or another currency as deemed appropriate by the Adviser. Forward foreign exchange contracts are valued at the forward rate and are marked-to-market daily. The change in market value is included in unrealized appreciation/depreciation on investments and foreign currency translations. When the contract is closed, the Fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed.

The use of forward foreign exchange contracts does not eliminate fluctuations in the underlying prices of the Fund’s portfolio securities, but it does establish a rate of exchange that can be achieved in the future. Although forward foreign exchange contracts limit the risk of loss due to a decline in the value of the hedged currency, they also limit any potential gain that might result should the value of the currency increase. At March 31, 2014, the Fund held no investments in forward foreign exchange contracts.

Limitations on the Purchase and Sale of Futures Contracts, Certain Options, and Swaps. Subject to the guidelines of the Board, the Fund may engage in “commodity interest” transactions (generally, transactions in futures, certain options, certain currency transactions, and certain types of swaps) only for bona fide hedging or other permissible transactions in accordance with the rules and regulations of the Commodity Futures Trading Commission (“CFTC”). Pursuant to amendments by the CFTC to Rule 4.5 under the Commodity Exchange Act (“CEA”), the Adviser has filed a notice of exemption from registration as a “commodity pool operator” with respect to the Fund. The Fund and the Adviser are therefore not subject to registration or regulation as a commodity pool operator under the CEA. In addition, certain trading restrictions are now applicable to the Fund as of January 1, 2013. These trading restrictions permit the Fund to engage in commodity interest transactions that include (i) “bona fide hedging” transactions, as that term is defined and interpreted by the CFTC and its staff, without regard to the percentage of the Fund’s assets committed to margin and options premiums and (ii) non-bona fide hedging transactions, provided that the Fund does not enter into such non-bona fide hedging

 

6


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited) (Continued)

 

 

 

transactions if, immediately thereafter, either (a) the sum of the amount of initial margin deposits on the Fund’s existing futures positions or swaps positions and option or swaption premiums would exceed 5% of the market value of the Fund’s liquidating value, after taking into account unrealized profits and unrealized losses on any such transactions, or (b) the aggregate net notional value of the Fund’s commodity interest transactions would not exceed 100% of the market value of the Fund’s liquidating value, after taking into account unrealized profits and unrealized losses on any such transactions. Therefore, in order to claim the Rule 4.5 exemption, the Fund is limited in its ability to invest in commodity futures, options, and certain types of swaps (including securities futures, broad based stock index futures, and financial futures contracts). As a result, in the future, the Fund will be more limited in its ability to use these instruments than in the past, and these limitations may have a negative impact on the ability of the Adviser to manage the Fund, and on the Fund’s performance.

Foreign Currency Translations. The books and records of the Fund are maintained in U.S. dollars. Foreign currencies, investments, and other assets and liabilities are translated into U.S. dollars at current exchange rates. Purchases and sales of investment securities, income, and expenses are translated at the exchange rate prevailing on the respective dates of such transactions. Unrealized gains and losses that result from changes in foreign exchange rates and/or changes in market prices of securities have been included in unrealized appreciation/depreciation on investments and foreign currency translations. Net realized foreign currency gains and losses resulting from changes in exchange rates include foreign currency gains and losses between trade date and settlement date on investment securities transactions, foreign currency transactions, and the difference between the amounts of interest and dividends recorded on the books of the Fund and the amounts actually received. The portion of foreign currency gains and losses related to fluctuation in exchange rates between the initial purchase trade date and subsequent sale trade date is included in realized gain/(loss) on investments.

Foreign Securities. The Fund may directly purchase securities of foreign issuers. Investing in securities of foreign issuers involves special risks not typically associated with investing in securities of U.S. issuers. The risks include possible revaluation of currencies, the inability to repatriate funds, less complete financial information about companies, and possible future adverse political and economic developments. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than securities of comparable U.S. issuers.

Foreign Taxes. The Fund may be subject to foreign taxes on income, gains on investments, or currency repatriation, a portion of which may be recoverable. The Fund will accrue such taxes and recoveries as applicable, based upon its current interpretation of tax rules and regulations that exist in the markets in which it invests.

Restricted Securities. The Fund may invest without limit in restricted securities. Restricted securities include securities whose disposition is subject to substantial legal or contractual restrictions. The sale of restricted securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted securities may sell at a price lower than similar securities that are not subject to restrictions on resale. Securities freely saleable among qualified institutional investors under special rules adopted by the SEC may be treated as liquid if they satisfy liquidity standards established by the Board. The continued liquidity of such securities is not as well assured as that of publicly traded securities, and accordingly the Board will monitor their liquidity. The Fund held no restricted securities at March 31, 2014.

 

7


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited) (Continued)

 

 

 

Tax Information. The Fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended.

Under the Regulated Investment Company Modernization Act of 2010, the Fund is permitted to carry forward for an unlimited period capital losses incurred. As a result of the rule, post-enactment capital losses that are carried forward will retain their character as either short term or long term capital losses.

 

8


THE GABELLI HEALTHCARE & WELLNESSRx TRUST

One Corporate Center

Rye, NY 10580-1422

Portfolio Management Team Biographies

Mario J. Gabelli, CFA, is Chairman and Chief Executive Officer of GAMCO Investors, Inc. that he founded in 1977 and Chief Investment Officer – Value Portfolios of Gabelli Funds, LLC and GAMCO Asset Management Inc. Mr. Gabelli is a summa cum laude graduate of Fordham University and holds an MBA degree from Columbia Business School and Honorary Doctorates from Fordham University and Roger Williams University.

Jeffrey J. Jonas, CFA, joined Gabelli in 2003 as a research analyst. He focuses on companies in the cardiovascular, healthcare services, and pharmacy benefits management sectors, among others. He also serves as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Funds Complex. Mr. Jonas was a Presidential Scholar at Boston College, where he received a BS in Finance and Management Information Systems.

Kevin V. Dreyer joined Gabelli in 2005 as a research analyst covering companies within the consumer sector. He currently serves as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Funds Complex. Mr. Dreyer received a BSE from the University of Pennsylvania and an MBA from Columbia Business School.

 

 

 

We have separated the portfolio managers’ commentary from the financial statements and investment portfolio due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers’ commentary is unrestricted. Both the commentary and the financial statements, including the portfolio of investments, will be available on our website at www.gabelli.com.

The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading “Specialized Equity Funds,” in Monday’s The Wall Street Journal. It is also listed in Barron’s Mutual Funds/Closed End Funds section under the heading “Specialized Equity Funds.”

The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting www.gabelli.com.

The NASDAQ symbol for the Net Asset Value is “XXGRX.”

 

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may from time to time purchase its common shares in the open market when the Fund’s shares are trading at a discount of 10% or more from the net asset value of the shares. The Fund may also, from time to time, purchase its preferred shares in the open market when the preferred shares are trading at a discount to the liquidation value.


 

THE GABELLI HEALTHCARE & WELLNESSRX TRUST

One Corporate Center

Rye, NY 10580-1422

 

t 800-GABELLI (800-422-3554)
f 914-921-5118
e info@gabelli.com
  GABELLI.COM

 

         
TRUSTEES    OFFICERS

Mario J. Gabelli, CFA

Chairman &

Chief Executive Officer,

GAMCO Investors, Inc.

 

Anthony J. Colavita

President,

Anthony J. Colavita, P.C.

 

James P. Conn

Former Managing Director &

Chief Investment Officer,

Financial Security Assurance

Holdings Ltd.

 

Vincent D. Enright

Former Senior Vice President &

Chief Financial Officer,

KeySpan Corp.

 

Robert C. Kolodny, MD

Physician,

Principal of KBS

Management LLC

 

Kuni Nakamura

President,

Advanced Polymer, Inc.

 

Anthonie C. van Ekris

Chairman,

BALMAC International, Inc.

 

Salvatore J. Zizza

Chairman,

Zizza & Associates Corp.

  

Agnes Mullady

President & Treasurer

 

Andrea R. Mango

Secretary

 

Richard J. Walz

Chief Compliance Officer

 

Carter W. Austin

Vice President

 

Wayne C. Pinsent, CFA

Vice President & Ombudsman

 

David I. Schachter

Vice President

 

Adam E. Tokar

Vice President

 

INVESTMENT ADVISER

 

Gabelli Funds, LLC

One Corporate Center

Rye, New York 10580-1422

 

CUSTODIAN

 

The Bank of New York Mellon

 

COUNSEL

 

Willkie Farr & Gallagher LLP

 

TRANSFER AGENT AND

REGISTRAR

 

Computershare Trust Company, N.A.

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

    

  

    

  
GRX Q1/2014     

LOGO

 


Item 2. Controls and Procedures.

 

  (a)

The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).

 

  (b)

There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d)) that occurred during the registrant’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 3. Exhibits.

Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Registrant)

 

The Gabelli Healthcare & WellnessRx Trust

 

By (Signature and Title)*

 

/s/ Agnes Mullady

 

 

Agnes Mullady, Principal Executive Officer and Principal

Financial Officer

 

Date

  5/16/2014

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By (Signature and Title)*

 

/s/ Agnes Mullady

 

 

Agnes Mullady, Principal Executive Officer and Principal

Financial Officer

 

Date

  5/16/2014

* Print the name and title of each signing officer under his or her signature.